Reduced-FOV excitation decreases susceptibility artifact in diffusion-weighted MRI with endorectal coil for prostate cancer detection

Magn Reson Imaging. 2015 Jan;33(1):56-62. doi: 10.1016/j.mri.2014.08.040. Epub 2014 Sep 6.


The purposes of this study were to determine if image distortion is less in prostate MR apparent diffusion coefficient (ADC) maps generated from a reduced-field-of-view (rFOV) diffusion-weighted-imaging (DWI) technique than from a conventional DWI sequence (CONV), and to determine if the rFOV ADC tumor contrast is as high as or better than that of the CONV sequence. Fifty patients underwent a 3T MRI exam. CONV and rFOV (utilizing a 2D, echo-planar, rectangularly-selective RF pulse) sequences were acquired using b=600, 0s/mm(2). Distortion was visually scored 0-4 by three independent observers and quantitatively measured using the difference in rectal wall curvature between the ADC maps and T2-weighted images. Distortion scores were lower with the rFOV sequence (p<0.012, Wilcoxon Signed-Rank Test, n=50), and difference in distortion scores did not differ significantly among observers (p=0.99, Kruskal-Wallis Rank Sum Test). The difference in rectal curvature was less with rFOV ADC maps (26%±10%) than CONV ADC maps (34%±13%) (p<0.011, Student's t-test). In seventeen patients with untreated, biopsy confirmed prostate cancer, the rFOV sequence afforded significantly higher ADC tumor contrast (44.0%) than the CONV sequence (35.9%), (p<0.0012, Student's t-test). The rFOV sequence yielded significantly decreased susceptibility artifact and significantly higher contrast between tumor and healthy tissue.

Keywords: ADC; Diffusion-weighted imaging; Endorectal; MRI; Prostate; Reduced FOV.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Automation
  • Biopsy
  • Diagnosis, Computer-Assisted
  • Diffusion Magnetic Resonance Imaging*
  • Humans
  • Image Processing, Computer-Assisted*
  • Male
  • Middle Aged
  • Observer Variation
  • Pattern Recognition, Automated*
  • Prospective Studies
  • Prostate-Specific Antigen / metabolism
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / pathology*
  • Rectum / pathology
  • Reproducibility of Results


  • Prostate-Specific Antigen